CN117062804A - 1,3-取代的环丁基衍生物及其用途 - Google Patents
1,3-取代的环丁基衍生物及其用途 Download PDFInfo
- Publication number
- CN117062804A CN117062804A CN202280024266.2A CN202280024266A CN117062804A CN 117062804 A CN117062804 A CN 117062804A CN 202280024266 A CN202280024266 A CN 202280024266A CN 117062804 A CN117062804 A CN 117062804A
- Authority
- CN
- China
- Prior art keywords
- pain
- pharmaceutically acceptable
- compound
- acceptable salt
- ocular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163166289P | 2021-03-26 | 2021-03-26 | |
| US63/166,289 | 2021-03-26 | ||
| PCT/IB2022/052720 WO2022201097A1 (en) | 2021-03-26 | 2022-03-24 | 1,3-substituted cyclobutyl derivatives and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117062804A true CN117062804A (zh) | 2023-11-14 |
Family
ID=80999265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280024266.2A Pending CN117062804A (zh) | 2021-03-26 | 2022-03-24 | 1,3-取代的环丁基衍生物及其用途 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11845730B2 (https=) |
| EP (1) | EP4313951A1 (https=) |
| JP (1) | JP2024510778A (https=) |
| KR (1) | KR20230162660A (https=) |
| CN (1) | CN117062804A (https=) |
| AR (1) | AR125196A1 (https=) |
| AU (1) | AU2022244467A1 (https=) |
| CA (1) | CA3214066A1 (https=) |
| IL (1) | IL307189A (https=) |
| MX (1) | MX2023011377A (https=) |
| PY (1) | PY2221203A (https=) |
| TW (1) | TW202304864A (https=) |
| UY (1) | UY39681A (https=) |
| WO (1) | WO2022201097A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR125196A1 (es) * | 2021-03-26 | 2023-06-21 | Novartis Ag | Derivados de ciclobutilo 1,3-sustituidos y sus usos |
| WO2024062389A1 (en) * | 2022-09-21 | 2024-03-28 | Bausch + Lomb Ireland Limited | Crystalline polymorph forms of a trpv1 antagonist and formulations thereof |
| US20240148709A1 (en) * | 2022-11-08 | 2024-05-09 | Aisa Pharma, Inc. | Methods of treating eye pain and eye disorders |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| US6933311B2 (en) * | 2003-02-11 | 2005-08-23 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| US7514562B2 (en) * | 2003-03-07 | 2009-04-07 | Glaxo Group Limited | Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain |
| GB0412769D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
| RU2451014C2 (ru) | 2005-07-22 | 2012-05-20 | Мотида Фармасьютикал Ко., Лтд. | Новое производное гетероциклиден ацетамида |
| EP2050734A1 (en) | 2006-07-13 | 2009-04-22 | Kyowa Hakko Kirin Co., Ltd. | Pentadienamide derivative |
| NZ577980A (en) | 2006-12-27 | 2012-01-12 | Sanofi Aventis | Cycloalkylamine substituted isoquinolone derivatives |
| WO2012072512A1 (en) * | 2010-11-29 | 2012-06-07 | Glaxo Group Limited | N-cyclobutyl-imidazopyridine or -pyrazolopyridine carboxamides as trpv1 antagonists |
| DE102010052781A1 (de) | 2010-11-30 | 2012-05-31 | Trw Automotive Gmbh | Befestigungsvorrichtung und Befestigungsbaugruppe zur Befestigung eines Gasgenerators und Fahrzeuginsassenrückhaltesystem |
| TW201302681A (zh) * | 2011-03-25 | 2013-01-16 | Abbott Lab | Ｔｒｐｖ１拮抗劑 |
| JP2014510768A (ja) * | 2011-04-11 | 2014-05-01 | グラクソ グループ リミテッド | Ｔｒｐｖ１アンタゴニストとしてのｎ−シクロブチルイミダゾピリジンメチルアミン |
| US9747862B2 (en) | 2015-11-02 | 2017-08-29 | Castar, Inc. | Method of immersive rendering for wide field of view |
| US10269906B2 (en) * | 2016-11-30 | 2019-04-23 | Taiwan Semiconductor Manufacturing Co., Ltd. | Semiconductor device having two spacers |
| WO2018151678A1 (en) * | 2017-02-15 | 2018-08-23 | Agency For Science, Technology And Research | Compounds for treatment of cancer and epigenetics |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| AU2019392904B9 (en) | 2018-12-07 | 2022-12-22 | University Of Maryland, Baltimore | Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitors |
| AR125196A1 (es) * | 2021-03-26 | 2023-06-21 | Novartis Ag | Derivados de ciclobutilo 1,3-sustituidos y sus usos |
-
2022
- 2022-03-22 AR ARP220100676A patent/AR125196A1/es unknown
- 2022-03-22 UY UY0001039681A patent/UY39681A/es unknown
- 2022-03-23 PY PY202202221203A patent/PY2221203A/es unknown
- 2022-03-24 JP JP2023558324A patent/JP2024510778A/ja active Pending
- 2022-03-24 EP EP22714016.7A patent/EP4313951A1/en active Pending
- 2022-03-24 CA CA3214066A patent/CA3214066A1/en active Pending
- 2022-03-24 AU AU2022244467A patent/AU2022244467A1/en active Pending
- 2022-03-24 US US17/656,313 patent/US11845730B2/en active Active
- 2022-03-24 WO PCT/IB2022/052720 patent/WO2022201097A1/en not_active Ceased
- 2022-03-24 CN CN202280024266.2A patent/CN117062804A/zh active Pending
- 2022-03-24 TW TW111111060A patent/TW202304864A/zh unknown
- 2022-03-24 KR KR1020237036535A patent/KR20230162660A/ko active Pending
- 2022-03-24 IL IL307189A patent/IL307189A/en unknown
- 2022-03-24 MX MX2023011377A patent/MX2023011377A/es unknown
-
2023
- 2023-10-24 US US18/493,441 patent/US12435040B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL307189A (en) | 2023-11-01 |
| AU2022244467A1 (en) | 2023-10-12 |
| JP2024510778A (ja) | 2024-03-11 |
| EP4313951A1 (en) | 2024-02-07 |
| AR125196A1 (es) | 2023-06-21 |
| PY2221203A (es) | 2022-11-24 |
| UY39681A (es) | 2022-10-31 |
| US12435040B2 (en) | 2025-10-07 |
| MX2023011377A (es) | 2023-10-06 |
| US11845730B2 (en) | 2023-12-19 |
| WO2022201097A1 (en) | 2022-09-29 |
| BR112023019496A2 (pt) | 2023-12-05 |
| US20220324811A1 (en) | 2022-10-13 |
| US20240308965A1 (en) | 2024-09-19 |
| TW202304864A (zh) | 2023-02-01 |
| CA3214066A1 (en) | 2022-09-29 |
| KR20230162660A (ko) | 2023-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12246008B2 (en) | 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels | |
| TWI736566B (zh) | Ｔｌｒ７/８拮抗劑及其用途 | |
| US10550102B2 (en) | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | |
| US12435040B2 (en) | 1,3-substituted cyclobutyl derivatives and uses thereof | |
| CN105085429B (zh) | 芳杂环类衍生物及其在药物上的应用 | |
| US9550762B2 (en) | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use | |
| US20220340573A1 (en) | 1,2,4-oxadiazole derivatives as liver x receptor agonists | |
| WO2024259171A9 (en) | Keap1 inhibitors and uses thereof | |
| TWI689497B (zh) | 芳雜環類衍生物及其在藥物中的應用 | |
| HK1254800A1 (zh) | 2，3，4，5-四氢吡啶-6-胺衍生物 | |
| WO2021139599A1 (zh) | RORγt抑制剂及其制备方法和用途 | |
| BR122025005591B1 (pt) | Uso de e processo para preparação de derivados de ciclobutila 1,3- substituída, combinação farmacêutica, e kit | |
| BR112023019496B1 (pt) | Derivados de ciclobutila 1,3-substituída, e composição farmacêutica | |
| TWI810547B (zh) | Pd-l1拮抗劑化合物 | |
| EA050893B1 (ru) | Производные 1,3-замещенного циклобутила и способы их применения | |
| BR122025005591A2 (pt) | Uso de e processo para preparação de derivados de ciclobutila 1,3-substituída, combinação farmacêutica, e kit | |
| US20250188069A1 (en) | Compounds and methods for degrading casein kinase 1 alpha | |
| HK40063935A (zh) | 多环tlr7/8拮抗剂及其在治疗免疫失调中的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20231123 Address after: Irish Dublin Applicant after: Bausch & Lomb Ireland Ltd. Address before: Basel, SUI Applicant before: NOVARTIS AG |
|
| TA01 | Transfer of patent application right | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |